Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952205 | 0.89 | NLRP3 (0.61) | NLRP3OPRM1OPRL1MAPTRXFP1 | |
| SCHEMBL23952170 | 0.88 | NLRP3 (0.64) | NLRP3OPRM1OPRL1MAPTRXFP1 | |
| SCHEMBL25819084 | 0.85 | NLRP3 (0.40) | NLRP3 | |
| SCHEMBL23952442 | 0.83 | NLRP3 (0.80) | NLRP3MAPTRXFP1NTRK1 | |
| SCHEMBL23952197 | 0.82 | NLRP3 (0.44) | NLRP3MAPTRXFP1 | |
| SCHEMBL30061709 | 0.81 | NLRP3 (0.72) | NLRP3MAPTRXFP1NTRK1 | |
| SCHEMBL23952458 | 0.81 | NLRP3 (0.72) | NLRP3MAPTRXFP1NTRK1 | |
| SCHEMBL23952174 | 0.80 | NLRP3 (0.65) | NLRP3NTRK1 | |
| SCHEMBL23952379 | 0.80 | NLRP3 (0.65) | NLRP3MAPTRXFP1NTRK1TP53 | |
| SCHEMBL30062266 | 0.80 | NLRP3 (0.65) | NLRP3MAPTRXFP1NTRK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| WO-2021209539-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885OPRM1 4481/4885OPRL1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.